Compare Rivian Automotive, Inc. (RIVN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Sanofi SA — how do they compare? Rivian Automotive, Inc. trades at $13.93 (market cap $20.75B), while Sanofi SA trades at $40.16 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 4.6× Rivian Automotive, Inc.'s market cap, and Sanofi SA pays a 6.01% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Sanofi SA for 94 Days on average.
| RIVN | SNY | |
|---|---|---|
Market Cap | $20.75B | $95.18B |
Volume | 26,144,654 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $52.34 |
52-Week Low | $12.50 | $39.51 |
Typical Hold Time | 61 Days | 94 Days |
Enterprise Value | $20.79B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $14.03, down 2.16% amid bearish technical signals despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving revenue trends and cash flow reduction. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show selling pressure with RSI near oversold levels.
Rivian presents a high-risk growth opportunity with significant operational improvements but persistent losses. The R2 SUV rollout and autonomy technology development offer long-term potential, while near-term challenges include cash burn and competitive EV market pressures. Investors should weigh improving fundamentals against substantial execution risks in a capital-intensive industry.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
